LLY Jun 2024 615.000 put
| Previous close | 0.0500 |
| Open | 0.0500 |
| Bid | 0.0100 |
| Ask | 4.3000 |
| Strike | 615.00 |
| Expiry date | 2024-06-07 |
| Day's range | 0.0500 - 0.0500 |
| Contract range | N/A |
| Volume | |
| Open interest | 5 |
- Yahoo Finance Video
Ro CEO on GLP-1 drug shortage: US healthcare is '1 of 1'
GLP-1 medication supply constraints have left many patients grappling with the challenge of accessing these highly sought-after drugs. Ro CEO Zach Reitano joins Asking for a Trend to shed light on how his company aims to make supply information more readily available to patients in need. Reitano underscores Ro's core mission of "building goal-oriented healthcare" tailored to the individual needs of its patients. Recently, the company has been dedicating its efforts to addressing obesity, but they have also recognized "a massive shortage" in the availability of GLP-1 drugs. Consequently, Ro has been proactively "building products and services to help patients navigate and manage through these supply challenges." Reitano characterizes the current US healthcare landscape as "one of one," noting that "never before in healthcare has the majority of the US population been eligible for a drug." This situation has led to patients and providers "desperately" wanting access to these therapies, resulting in severe supply-demand dynamics, a challenge Reitano believes could persist for years to come. Reitano explains Ro's goal is to "crowdsource" supply information with its tracker, streamlining the process of accessing these drugs for both patients and healthcare providers. For more expert insight and the latest market action, click here to watch this full episode of Asking for a Trend. This post was written by Angel Smith
Insider MonkeyIs Eli Lilly And Co (NYSE:LLY) the Best Weight Loss Stock to Buy in 2024?
We recently published a list of Jim Cramer’s Top 10 Stock Picks for June. Since Eli Lilly And Co (NYSE:LLY) ranks higher in the list, the stock deserves a deeper look. But first, let’s see what Cramer was talking about during his programs earlier this week. Jim Cramer in a latest program lamented over Salesforce’s […]
BloombergGoldman Sees Obesity-Drug Market Growing to $130 Billion by 2030
(Bloomberg) -- Goldman Sachs Group Inc. sees growing potential for the global market for weight-loss drugs by the end of the decade.Most Read from BloombergWall Street Billionaires Are Rushing to Back Trump, Verdict Be DamnedDonald Trump Becomes First Former US President Guilty of CrimesSouth Africa Election Results With 29% Voting Districts InTrump Is Guilty on All Counts in Hush-Money Case. Now What?World’s Largest Nuclear Plant Sits Idle While Energy Needs SoarThe obesity market — currently d
